• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday

    2/28/24 8:07:42 AM ET
    $ANF
    $APLS
    $AXON
    $ECL
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANF alert in real time by email

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

    • Oppenheimer boosted the price target for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) from $55 to $59. Oppenheimer analyst Francois Brisebois reiterated an Outperform rating. Tarsus Pharmaceuticals shares gained 18.3% to close at $39.22 on Tuesday. See how other analysts view this stock.
    • Wedbush increased the price target for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) from $60 to $67. Wedbush analyst Laura Chico maintained a Neutral rating. Apellis Pharmaceuticals shares fell 3.3% to close at $69.35 on Tuesday. See how other analysts view this stock.
    • Needham increased Axon Enterprise, Inc. (NASDAQ:AXON) price target from $240 to $315. Needham analyst Joshua Reilly maintained a Buy rating. Axon Enterprise shares rose 0.1% to close at $271.82 on Tuesday. See how other analysts view this stock.
    • Mizuho slashed the price target for Essex Property Trust, Inc. (NYSE:ESS) from $255 to $250. Mizuho analyst Vikram Malhorta upgraded the stock from Neutral to Buy. Essex Property Trust shares gained 0.9% to close at $227.73 on Tuesday. See how other analysts view this stock.
    • Raymond James lowered Integral Ad Science Holding Corp. (NASDAQ:IAS) price target from $20 to $16. Raymond James analyst Andrew Marok downgraded the stock from Strong Buy to Outperform. Integral Ad Science shares gained 1.4% to close at $17.10 on Tuesday. See how other analysts view this stock.
    • DA Davidson boosted the price target for Sterling Infrastructure, Inc. (NASDAQ:STRL) from $86 to $115. DA Davidson analyst Brent Thielman downgraded the stock from Buy to Neutral. Sterling Infrastructure shares climbed 18.1% to close at $106.22 on Tuesday. See how other analysts view this stock.
    • Needham boosted LendingTree, Inc. (NASDAQ:TREE) price target from $17 to $40. Needham analyst Mayank Tandon maintained a Buy rating. LendingTree shares fell 4.8% to close at $32.62 on Tuesday. See how other analysts view this stock.
    • Keybanc boosted ICU Medical, Inc. (NASDAQ:ICUI) price target from $134 to $136. Keybanc analyst Brett Fishbin maintained an Overweight rating. ICU Medical shares climbed 1.2% to close at $106.81 on Tuesday. See how other analysts view this stock.
    • Barclays raised Ecolab Inc. (NYSE:ECL) price target from $225 to $260. Barclays analyst Manav Patnaik upgraded the stock from Equal-Weight to Overweight. Ecolab shares gained 0.8% to close at $222.09 on Tuesday. See how other analysts view this stock.
    • Telsey Advisory Group increased Abercrombie & Fitch Co. (NYSE:ANF) price target from $105 to $140. Telsey Advisory Group maintained an Outperform rating. Abercrombie & Fitch shares fell 0.3% to close at $125.78 on Tuesday. See how other analysts view this stock.

     

    Check This Out: These 3 Energy Stocks With Over 5% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts

    Get the next $ANF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANF
    $APLS
    $AXON
    $ECL

    CompanyDatePrice TargetRatingAnalyst
    Ecolab Inc.
    $ECL
    3/16/2026$326.00Hold → Buy
    Berenberg
    Apellis Pharmaceuticals Inc.
    $APLS
    3/13/2026$31.00Buy
    Roth Capital
    Essex Property Trust Inc.
    $ESS
    2/27/2026Outperform → Mkt Perform
    Raymond James
    Sterling Infrastructure Inc.
    $STRL
    2/12/2026$486.00Buy
    Stifel
    Apellis Pharmaceuticals Inc.
    $APLS
    1/28/2026$24.00Equal Weight
    Barclays
    Ecolab Inc.
    $ECL
    1/23/2026Buy → Hold
    Erste Group
    Sterling Infrastructure Inc.
    $STRL
    1/23/2026$413.00Overweight
    Cantor Fitzgerald
    Apellis Pharmaceuticals Inc.
    $APLS
    1/21/2026$28.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ANF
    $APLS
    $AXON
    $ECL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ecolab Named One of the World's Most Ethical Companies for 20th Consecutive Year

    Ecolab is just one of six organizations recognized each year since the award's inception Ecolab Inc., a global leader in water, hygiene and infection prevention solutions and services that protect people and the resources vital to life, today announced it has been named one of the 2026 World's Most Ethical Companies® by Ethisphere, a global leader in defining and advancing the standards of ethical business practices. This marks Ecolab's 20th consecutive year receiving the recognition—an achievement only a small number of companies worldwide can claim. "At Ecolab, strong performance starts and ends with doing what's right," said Christophe Beck, Chairman and CEO, Ecolab. "For 20 years, t

    3/18/26 6:00:00 AM ET
    $ECL
    Package Goods/Cosmetics
    Consumer Discretionary

    Ecolab Schedules Webcast and Conference Call on April 28, 2026

    Ecolab will host a live webcast to discuss its first quarter 2026 results. A news release containing first quarter results is expected to be issued before market open on April 28, 2026. Details for the public webcast are as follows: TIME: 1:00 p.m. Eastern Time DATE: Tuesday, April 28, 2026 DURATION: One hour LOCATION: www.ecolab.com/investor ARCHIVE: A replay of the webcast and supplemental data will be available on Ecolab's website. About Ecolab A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global leader in water, hygiene and infection prevention solutions and services that protect people an

    3/17/26 4:00:00 PM ET
    $ECL
    Package Goods/Cosmetics
    Consumer Discretionary

    Ecolab Announces Global 10-14% Energy Surcharge

    Ecolab today reaffirmed its long-term commitment to secure supply and ensure service to any customer, anywhere in the world, amid sharply rising global energy costs and sourcing challenges. As part of our ongoing efforts to manage extraordinary cost pressures while continuing to deliver incremental total value to customers, we will implement a global 10-14% energy surcharge, depending on local market conditions, on all our products and services, effective April 1, 2026, applicable to all businesses and countries. Due to the war in the Middle East, global energy markets have experienced significant price volatility in recent weeks driven by supply disruptions, transportation constraints, a

    3/12/26 8:00:00 AM ET
    $ECL
    Package Goods/Cosmetics
    Consumer Discretionary

    $ANF
    $APLS
    $AXON
    $ECL
    SEC Filings

    View All

    SEC Form 144 filed by Tarsus Pharmaceuticals Inc.

    144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

    3/19/26 4:43:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Tarsus Pharmaceuticals Inc.

    144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

    3/19/26 4:38:18 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Tarsus Pharmaceuticals Inc.

    144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

    3/19/26 4:30:57 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANF
    $APLS
    $AXON
    $ECL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ecolab upgraded by Berenberg with a new price target

    Berenberg upgraded Ecolab from Hold to Buy and set a new price target of $326.00

    3/16/26 8:32:38 AM ET
    $ECL
    Package Goods/Cosmetics
    Consumer Discretionary

    Roth Capital initiated coverage on Apellis Pharmaceuticals with a new price target

    Roth Capital initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $31.00

    3/13/26 8:46:55 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Essex Property downgraded by Raymond James

    Raymond James downgraded Essex Property from Outperform to Mkt Perform

    2/27/26 8:28:37 AM ET
    $ESS
    Real Estate Investment Trusts
    Real Estate

    $ANF
    $APLS
    $AXON
    $ECL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Maclennan David bought $193,198 worth of shares (750 units at $257.60), increasing direct ownership by 3% to 23,035 units (SEC Form 4)

    4 - ECOLAB INC. (0000031462) (Issuer)

    12/8/25 4:25:04 PM ET
    $ECL
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Greenberg David C. bought $151,698 worth of shares (1,200 units at $126.42), increasing direct ownership by 18% to 7,960 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    8/27/25 5:51:17 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    Director Maclennan David bought $167,108 worth of shares (600 units at $278.51), increasing direct ownership by 3% to 20,253 units (SEC Form 4)

    4 - ECOLAB INC. (0000031462) (Issuer)

    8/15/25 4:43:26 PM ET
    $ECL
    Package Goods/Cosmetics
    Consumer Discretionary

    $ANF
    $APLS
    $AXON
    $ECL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Whitfield Dianne C.

    4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

    3/19/26 7:04:57 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Wahl Bryan

    4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

    3/19/26 7:04:44 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Neervannan Seshadri

    4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

    3/19/26 7:04:31 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANF
    $APLS
    $AXON
    $ECL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

    Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

    Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

    Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:29:16 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANF
    $APLS
    $AXON
    $ECL
    Leadership Updates

    Live Leadership Updates

    View All

    Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

    WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company's board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.  "We are thrilled to welcome Mikael to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Mikael is a proven industry leader with deep experience developing innovative medicine

    3/2/26 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ecolab Appoints Darrell Brown as Co-COO, Global Markets and Greg Cook as Co-COO, Global Businesses

    Ecolab Inc. has announced that to support its next phase of growth, it is dividing the chief operating officer role into two complementary positions to build high-performing global businesses while strengthening the foundations for growth in all our markets around the world. As part of these changes, Darrell R. Brown has been appointed Co-COO, Global Markets, and Greg B. Cook has been appointed Co-COO, Global Businesses, effective April 1. "We ended 2025 with strong momentum, and with that we are increasing our focus and leadership intensity to continue driving strong performance," said Christophe Beck, Ecolab chairman and chief executive officer. "Darrell has been an exceptional partner

    2/25/26 4:30:00 PM ET
    $ECL
    Package Goods/Cosmetics
    Consumer Discretionary

    Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

    IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. "David is one of the most accomplished leaders in eye care, with a strong track record of translating innovation into global impact," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "His experience building some of the most successful franchises in our industry will be invaluable as we scale XDEMVY, advance our pipeline and position Tarsus for sustained growth. We are honored

    2/18/26 8:30:00 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANF
    $APLS
    $AXON
    $ECL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integral Ad Science Holding Corp.

    SC 13G/A - INTEGRAL AD SCIENCE HOLDING CORP. (0001842718) (Subject)

    11/14/24 6:19:26 PM ET
    $IAS
    Computer Software: Programming Data Processing
    Technology

    $ANF
    $APLS
    $AXON
    $ECL
    Financials

    Live finance-specific insights

    View All

    Ecolab Schedules Webcast and Conference Call on April 28, 2026

    Ecolab will host a live webcast to discuss its first quarter 2026 results. A news release containing first quarter results is expected to be issued before market open on April 28, 2026. Details for the public webcast are as follows: TIME: 1:00 p.m. Eastern Time DATE: Tuesday, April 28, 2026 DURATION: One hour LOCATION: www.ecolab.com/investor ARCHIVE: A replay of the webcast and supplemental data will be available on Ecolab's website. About Ecolab A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global leader in water, hygiene and infection prevention solutions and services that protect people an

    3/17/26 4:00:00 PM ET
    $ECL
    Package Goods/Cosmetics
    Consumer Discretionary

    Abercrombie & Fitch Co. Reports Fourth Quarter and Full Year Results

    Company delivers record fourth quarter and full year net sales of $1.7 billion and $5.3 billion, respectivelyFourth quarter net sales grew 5% to 2024, with balanced growth across regions, brands and channelsFull year net sales grew 6% to 2024, with growth across regions and channelsHollister brands delivers record full year 2025 net sales on growth of 15%, with Abercrombie down 1% Full year operating margin of 13.3%, and net income per diluted share of $10.46Full year share repurchases of $450 million, or 5.4 million shares, representing 11% of shares outstanding at February 1, 2025Provides full year 2026 outlook for net sales growth in the range of 3% to 5%, operating margin in the range of

    3/4/26 7:30:00 AM ET
    $ANF
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    LENDINGTREE REPORTS FOURTH QUARTER 2025 RESULTS

    Consolidated revenue of $319.7 millionGAAP net income of $144.7 million or $10.27 per diluted share, inclusive of $146.4 million tax benefit to reduce the full valuation allowance against our net deferred tax assetsVariable marketing margin (VMM) of $92.0 millionAdjusted EBITDA of $36.7 millionAdjusted net loss per share of $(0.39)CHARLOTTE, N.C., March 2, 2026 /PRNewswire/ -- LendingTree, Inc. (NASDAQ:TREE), operator of LendingTree.com, the nation's leading online financial services marketplace, today announced results for the quarter ended December 31, 2025. The Company has posted a shareholder letter on its investor relations website at investors.lendingtree.com.

    3/2/26 4:15:00 PM ET
    $TREE
    Finance: Consumer Services
    Finance